Compare Docusign Inc (DOCU) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Zoetis Inc — how do they compare? Docusign Inc trades at $57.55 (market cap $11.33B), while Zoetis Inc trades at $72.96 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 2.7× Docusign Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Docusign Inc pays none. Which is the better fit depends on your goals.
| DOCU | ZTS | |
|---|---|---|
Market Cap | $11.33B | $31.14B |
Sector | Technology | Health |
52-Week High | $85.01 | $156.76 |
52-Week Low | $41.75 | $71.91 |
Enterprise Value | $10.70B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $57.89, down 2.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.09 exceeding expectations. Revenue growth remains steady, reaching $2.98B in 2025, while profitability improved significantly with a net income margin of 35.87%.
The outlook is mixed with solid fundamentals supporting long-term growth, but valuation multiples appear elevated. Key risks include competitive pressures and market volatility. Analyst consensus is cautious with a $55.40 price target below current levels, suggesting limited near-term upside despite positive operational trends.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
